GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sinocare Inc (SZSE:300298) » Definitions » Operating Income

Sinocare (SZSE:300298) Operating Income : ¥506 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Sinocare Operating Income?

Sinocare's Operating Income for the three months ended in Mar. 2024 was ¥119 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥506 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Sinocare's Operating Income for the three months ended in Mar. 2024 was ¥119 Mil. Sinocare's Revenue for the three months ended in Mar. 2024 was ¥1,014 Mil. Therefore, Sinocare's Operating Margin % for the quarter that ended in Mar. 2024 was 11.70%.

Warning Sign:

Sinocare Inc operating margin has been in a 5-year decline. The average rate of decline per year is -14.3%.

Sinocare's 5-Year average Growth Rate for Operating Margin % was -14.30% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sinocare's annualized ROC % for the quarter that ended in Mar. 2024 was 8.87%. Sinocare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 24.06%.


Sinocare Operating Income Historical Data

The historical data trend for Sinocare's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocare Operating Income Chart

Sinocare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 403.04 427.30 369.38 482.88 459.52

Sinocare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.68 151.68 160.18 75.98 118.56

Sinocare Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥506 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinocare  (SZSE:300298) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sinocare's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=474.228 * ( 1 - 15.75% )/( (4465.419 + 4543.916)/ 2 )
=399.53709/4504.6675
=8.87 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5926.972 - 654.336 - ( 816.038 - max(0, 1299.124 - 2106.341+816.038))
=4465.419

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5819.717 - 603.202 - ( 672.599 - max(0, 1173.834 - 1998.458+672.599))
=4543.916

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sinocare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=486.992/( ( (1828.828 + max(139.068, 0)) + (1838.549 + max(241.653, 0)) )/ 2 )
=486.992/( ( 1967.896 + 2080.202 )/ 2 )
=486.992/2024.049
=24.06 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(478.22 + 632.445 + 142.069) - (654.336 + 0 + 459.33)
=139.068

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(547.319 + 622.683 + 127.794) - (603.202 + 0 + 452.941)
=241.653

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Sinocare's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=118.557/1013.58
=11.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sinocare Operating Income Related Terms

Thank you for viewing the detailed overview of Sinocare's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocare (SZSE:300298) Business Description

Traded in Other Exchanges
N/A
Address
No.265 Guyuan Road, Hi-tech Zone, Hunan Province, Changsha, CHN, 410205
Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.
Executives
Li Shao Bo Directors, executives
Che Hong Jing Director
Wang Shi Min Executives
Huang An Guo Directors, executives
Directors, executives
Pan Shu Guang Securities Affairs Representative
Zhou Qing Hua Supervisors
Ning Gui Chun Supervisors
Wang Rui Securities Affairs Representative
Chen Ji Dong Supervisors
Che Hong Li Directors, executives
Zhang Fan Director

Sinocare (SZSE:300298) Headlines

No Headlines